Education
About Us
Working with TipRanks
Follow Us
BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
BMRN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$52.93 - $93.04
Previous CloseN/A
Volume465.01K
Average Volume (3M)2.21M
Market Cap
$11.03B
Enterprise Value$10.01B
Total Cash (Recent Filing)$1.43B
Total Debt (Recent Filing)$603.87M
Price to Earnings (P/E)17.0
Beta0.45
Next Earnings
Oct 22, 2025EPS Estimate
0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.23
Shares Outstanding192,014,600
10 Day Avg. Volume1,815,937
30 Day Avg. Volume2,207,138
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue3.27
Enterprise Value/Gross Profit4.11
Enterprise Value/Ebitda11.19
Forecast
1Y Price Target
$98.77Price Target Upside71.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering24
Bulls Say, Bears Say
Bulls Say
Financial PerformanceBMRN reported higher than expected second quarter total sales of $825M, an 11% QoQ increase.
Revenue GrowthVoxzogo's strong global expansion led to revenue growth, with revenue at $221 million, above estimates and consensus.
Bears Say
Market CompetitionImpending Voxzogo competition is expected by year-end, which could impact its market position.
Patent IssuesThe EU patent Board's preliminary decision suggests that a BioMarin patent lacks disclosure needed to differentiate from prior art.
BioMarin Pharmaceutical News
BMRN FAQ
What was BioMarin Pharmaceutical’s price range in the past 12 months?
BioMarin Pharmaceutical lowest stock price was $52.93 and its highest was $93.04 in the past 12 months.
What is BioMarin Pharmaceutical’s market cap?
BioMarin Pharmaceutical’s market cap is $11.03B.
When is BioMarin Pharmaceutical’s upcoming earnings report date?
BioMarin Pharmaceutical’s upcoming earnings report date is Oct 22, 2025 which is in 56 days.
How were BioMarin Pharmaceutical’s earnings last quarter?
BioMarin Pharmaceutical released its earnings results on Aug 04, 2025. The company reported $1.23 earnings per share for the quarter, beating the consensus estimate of $0.861 by $0.369.
Is BioMarin Pharmaceutical overvalued?
According to Wall Street analysts BioMarin Pharmaceutical’s price is currently Undervalued.
Does BioMarin Pharmaceutical pay dividends?
BioMarin Pharmaceutical does not currently pay dividends.
What is BioMarin Pharmaceutical’s EPS estimate?
BioMarin Pharmaceutical’s EPS estimate is 0.87.
How many shares outstanding does BioMarin Pharmaceutical have?
BioMarin Pharmaceutical has 192,014,600 shares outstanding.
What happened to BioMarin Pharmaceutical’s price movement after its last earnings report?
BioMarin Pharmaceutical reported an EPS of $1.23 in its last earnings report, beating expectations of $0.861. Following the earnings report the stock price went up 2.686%.
Which hedge fund is a major shareholder of BioMarin Pharmaceutical?
Currently, no hedge funds are holding shares in BMRN
BioMarin Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$98.77 (71.92% Upside)
$98.77 (71.92% Upside)
Blogger Sentiment
Bullish
BMRN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 3.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 13.5%
Last 30 Days ▲ 13.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.15%
12-Months-Change
Fundamentals
Return on Equity
11.62%
Trailing 12-Months
Asset Growth
5.51%
Trailing 12-Months
Company Description
BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing and commercializing innovative biopharmaceuticals for serious diseases and medical conditions. The company primarily operates in the field of rare genetic disorders and has a strong portfolio of products that includes therapies for conditions such as phenylketonuria (PKU), dwarfism, and other metabolic disorders. BioMarin's commitment to research and development drives its pipeline of new therapies, aiming to address unmet medical needs in the rare disease space.
BMRN Company Deck
BMRN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
BioMarin Pharmaceuticals reported strong revenue growth, successful acquisition of Inozyme, and significant progress in their pipeline, which were slightly offset by increased operating expenses and adjusted revenue guidance for VOXZOGO.View all BMRN earnings summariesBMRN Revenue Breakdown
28.98% VIMIZIM
19.42% VOXZOGO
17.37% NAGLAZYME
12.56% PALYNZIQ
21.66% Other
BMRN Stock 12 Month Forecast
Average Price Target
$98.77
▲(71.92% Upside)
Technical Analysis
Ownership Overview
0.54% Insiders
31.09% Mutual Funds
35.95% Other Institutional Investors
9.58% Public Companies and Individual Investors